Global Anti-Ischemic Agents Market by Type (Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates), Indication (Angina Pectoris, Ischemic Stroke, Myocardial Infarction), Route of Administration, End-User - Forecast 2024-2030- Product Image

Sale

Global Anti-Ischemic Agents Market by Type (Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates), Indication (Angina Pectoris, Ischemic Stroke, Myocardial Infarction), Route of Administration, End-User - Forecast 2024-2030

Report
184 Pages
March 2024
Region: Global
360iResearch™
ID: 5887511

UP TO €845EUR$875USD£723GBP OFF until Dec 31^st 2024

The Anti-Ischemic Agents Market size was estimated at USD 355.88 million in 2023, USD 378.99 million in 2024, and is expected to grow at a CAGR of 6.23% to reach USD 543.43 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Ischemic Agents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Ischemic Agents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Ischemic Agents Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, AstraZeneca, Baxter, Inc., Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Cipla Ltd., Dr Reddy's Laboratories Ltd., Eli Lily & Company, Eris Lifesciences Ltd., FDC Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., J B Chemicals and Pharmaceuticals Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Medley Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Ltd., Novartis AG, Pfizer, Inc., Torrent Pharmaceuticals Ltd., Troikaa Pharmaceuticals Ltd., and Zydus Lifesciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Anti-Ischemic Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Antiplatelet Agents
- Calcium Channel Blockers
- Organic Nitrates
- Potassium Channel Openers
- ß-Blockers
Indication
- Angina Pectoris
- Ischemic Stroke
- Myocardial Infarction
- Peripheral Artery Diseases
Route of Administration
- Intravenous (IV)
- Oral
- Transdermal
End-User
- Ambulatory Care
- Homecare
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Anti-Ischemic Agents Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Ischemic Agents Market?
What are the technology trends and regulatory frameworks in the Anti-Ischemic Agents Market?
What is the market share of the leading vendors in the Anti-Ischemic Agents Market?
Which modes and strategic moves are suitable for entering the Anti-Ischemic Agents Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Anti-Ischemic Agents Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Changing lifestyles and rising prevalence of ischemic conditions
5.1.1.2. Increasing utilization of advanced diagnostic tools and techniques for ischemic conditions
5.1.1.3. Surge in research activities for developing new anti-ischemic agents
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Ongoing innovations and investment in drug development activities
5.1.3.2. Collaborative efforts among various stakeholders for clinical trials
5.1.4. Challenges
5.1.4.1. Associated side-effects and safety concerns
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Anti-Ischemic Agents Market, by Type

6.1. Introduction
6.2. Antiplatelet Agents
6.3. Calcium Channel Blockers
6.4. Organic Nitrates
6.5. Potassium Channel Openers
6.6. ß-Blockers

7. Anti-Ischemic Agents Market, by Indication

7.1. Introduction
7.2. Angina Pectoris
7.3. Ischemic Stroke
7.4. Myocardial Infarction
7.5. Peripheral Artery Diseases

8. Anti-Ischemic Agents Market, by Route of Administration

8.1. Introduction
8.2. Intravenous (IV)
8.3. Oral
8.4. Transdermal

9. Anti-Ischemic Agents Market, by End-User

9.1. Introduction
9.2. Ambulatory Care
9.3. Homecare
9.4. Hospitals

10. Americas Anti-Ischemic Agents Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Anti-Ischemic Agents Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Anti-Ischemic Agents Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
14.1.1. Alembic Pharmaceuticals Limited
14.1.2. AstraZeneca
14.1.3. Baxter, Inc.
14.1.4. Bayer AG
14.1.5. Boehringer Ingelheim
14.1.6. Bristol Myers Squibb
14.1.7. Cipla Ltd.
14.1.8. Dr Reddy's Laboratories Ltd.
14.1.9. Eli Lily & Company
14.1.10. Eris Lifesciences Ltd.
14.1.11. FDC Ltd.
14.1.12. Glenmark Pharmaceuticals Ltd.
14.1.13. Intas Pharmaceuticals Ltd.
14.1.14. Ipca Laboratories Ltd.
14.1.15. J B Chemicals and Pharmaceuticals Ltd.
14.1.16. Lupin Ltd.
14.1.17. Macleods Pharmaceuticals Pvt Ltd.
14.1.18. Medley Pharmaceuticals Ltd.
14.1.19. Micro Labs Ltd.
14.1.20. Natco Pharma Ltd.
14.1.21. Novartis AG
14.1.22. Pfizer, Inc.
14.1.23. Torrent Pharmaceuticals Ltd.
14.1.24. Troikaa Pharmaceuticals Ltd.
14.1.25. Zydus Lifesciences Ltd.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing

List of Figures

FIGURE 1. ANTI-ISCHEMIC AGENTS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTI-ISCHEMIC AGENTS MARKET DYNAMICS
FIGURE 7. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. ANTI-ISCHEMIC AGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORGANIC NITRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY POTASSIUM CHANNEL OPENERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ?-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 193. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. ANTI-ISCHEMIC AGENTS MARKET LICENSE & PRICING

Companies Mentioned

Alembic Pharmaceuticals Limited
AstraZeneca
Baxter, Inc.
Bayer AG
Boehringer Ingelheim
Bristol Myers Squibb
Cipla Ltd.
Dr Reddy's Laboratories Ltd.
Eli Lily & Company
Eris Lifesciences Ltd.
FDC Ltd.
Glenmark Pharmaceuticals Ltd.
Intas Pharmaceuticals Ltd.
Ipca Laboratories Ltd.
J B Chemicals and Pharmaceuticals Ltd.
Lupin Ltd.
Macleods Pharmaceuticals Pvt Ltd.
Medley Pharmaceuticals Ltd.
Micro Labs Ltd.
Natco Pharma Ltd.
Novartis AG
Pfizer, Inc.
Torrent Pharmaceuticals Ltd.
Troikaa Pharmaceuticals Ltd.
Zydus Lifesciences Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	184
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 378.99 Million
Forecasted Market Value ( USD ) by 2030	$ 543.43 Million
Compound Annual Growth Rate	6.2%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3259EUR$3,374USD£2,789GBP €3621EUR$3,749USD£3,099GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4128EUR$4,274USD£3,533GBP €4587EUR$4,749USD£3,925GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4997EUR$5,174USD£4,276GBP €5552EUR$5,749USD£4,752GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5866EUR$6,074USD£5,020GBP €6518EUR$6,749USD£5,578GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7605EUR$7,874USD£6,508GBP €8450EUR$8,749USD£7,231GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Anti-Ischemic Agents - Global Strategic Business Report

Global Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Forecast 2024-2030

Transient Ischemic Attack - Pipeline Insight, 2024

Calcium Channel Blocker Global Market Report 2024

Global Pulmonary Arterial Hypertension Market by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5), Distribution (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030

About the Ischemic Attack Drug Market